E-Cadherin and EpCAM expression by NSCLC tumour cells associate with normal fibroblast activation through a pathway initiated by integrin αvβ6 and maintained through TGFβ signalling

Abstract

Fibroblasts in the tumour stroma (cancer-associated fibroblasts) influence tumour progression and response to therapeutics; little is known about the mechanisms through which the tumour cell co-opts a normal fibroblast. To study the activation of fibroblasts by tumour cells, a panel of non-small cell lung cancer (NSCLC) cell lines and normal human dermal fibroblasts were co-cultured. A subset of the NSCLC cells induced an activated cancer-associated fibroblast-like fibroblast phenotype defined by induction of fibroblast α-smooth muscle actin expression. Tumour cells that activated fibroblasts were associated with E-Cadherin and EpCAM expression and expression of integrin αvβ6. Co-culture of activating tumour cells with fibroblasts resulted in induction of transcripts associated with tumour cell invasion and growth, TGFβ1 and TGFBR1, SERPINE-1, BMP6, SPHK1 and MMP9. Fibroblast activation was inhibited by an αvβ6/8 integrin blocking antibody (264RAD) and a small molecule inhibitor of the TGF-beta type I receptor activin-like kinase (ALK5) (SB431542), demonstrating that transactivation of the TGFβ pathway initiates fibroblast activation. Both integrin and ALK5 antagonists inhibited initiation. Only ALK5 was effective when added after 3 days of co-culture. This suggests that although activation is αvβ6-dependent, once fibroblasts are activated alternative TGFβ pathway regulators maintain an activation loop. In co-culture activating cells had reduced sensitivity to selumetinib, AZD8931 and afatinib compared with mono-culture. In contrast, non-activating cells were insensitive to selumetinib and AZD8931 in both mono-culture and co-culture. In conclusion NSCLC cell lines, positive for E-Cadherin, EpCAM and αvβ6 expression, activate normal fibroblasts through avβ6/TGFβ signalling in vitro, and influence both gene expression and response to therapeutic agents.

RETRACTED ARTICLE: CXCL12/CXCR4 Axis Upregulates Twist to Induce EMT in Human Glioblastoma

“…Up to now, many putative signaling pathways, involving canonical transforming growth factor β, VEGF, and Snail, have been identified to participate in the EMT progression in different types of cancers [9][10][11][12]. Once the EMT occurred, E-cadherin exerts a biological effect on the regulation of cell-cell interactions, leading to invasion and dissemination of cancer cells [13,14].…”

Role of tumor microenvironment in tumorigenesis

“…For instance, Galectin-1 overexpression in CAFs advances the development of abutting cancer cells 45 and is correlated with poor prognosis in several types of cancer, including breast and prostate cancer and laryngeal carcinoma 46-49. Chemokine (C-X-C motif) ligand 12 (CXCL12), violently uttered in CAFs, may induce epithelial-mesenchymal transition (EMT) of cancer cells to promote cancer progress in gastric and prostate cancers 50, 51. Moreover, one team discovered that MMP-2, derived from senescent CAF-CMs, induced epithelial invasion and keratinocyte discohesion into collagen.…”

Sunitinib, a Small-Molecule Kinase Inhibitor, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice

“…During the progression of IPF, the chronic injuries incite the abnormally activated alveolar epithelial cells (AECs) to secrete TGF-β, which in turn promotes the EMT, by which AECs undergo mesenchymal transformation, lose their cell-cell adhesion, acquire migratory and invasive properties, and ultimately convert into mesenchymal cells, accounting for excessive deposition of ECM in parenchymal . TGF-β signaling is essential in a number of profibrotic events including EMT, fibroblast activation and eventual ECM deposition (Yang et al 2014;Eberlein et al 2015;Okumura et al 2015;Zerr et al 2016). Sunitinib profoundly inhibited TGF-β-induced EMT (Fig.…”